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ABSTRACT: Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of 
cancer mortality. The study aimed to assess the level of urea, creatinine and cystatin C in prostate cancer subjects. The 
subjects consisted of 92 adult males between the ages of 45 to 70 years; 46 prostate cancer subjects and 46 apparently 
healthy subjects recruited from a Teaching Hospital in Nigeria. Urea and creatinine were estimated by colorimetric 
method, cystatin C was estimated using Enzyme linked immunosorbent assay (ELISA) technique. The results obtained 
showed that urea and creatinine were significantly high (p<0.05) while cystatin C was significantly low (p<0.05) in 
prostate cancer subjects compared with control subjects. Cystatin C was significantly high (p<0.05) in prostate cancer 
subjects on treatment compared with subjects not on treatment but there was no significant difference (p>0.05) in the 
levels of urea and creatinine. The research concluded that increased serum urea and creatinine concentrations as well 
as decreased cystatin C level may pose higher risk of renal dysfunction in prostate cancer subjects. Thus, the levels of 
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Prostate cancer (PC), an adenocarcinoma of the male 
prostate gland, has increasingly become an important 
health burden among men in the world (Ferlay et al., 
2011; Lozano et al., 2012). Prostate cancer is the 
fourth most common cancer in both sexes combined 
and the second most common cancer in men. 
Infection or inflammation of the prostate (prostatitis) 
may increase the chance for prostate cancer especially 
infection with the sexually transmitted infections such 
as chlamydia, gonorrhea, or syphilis (Dennis et al., 
2002). Whilst the primary risk factors include age and 
family history, other factors associated with cancer 
include hormonal imbalances, the living and working 
environment, lifestyle and diet, sexually transmitted 
infections, and exposure to certain medications (Grove 
et al., 2002). Over time, cancer cells begin to multiply 
and spread to the surrounding prostate tissue 
(the stroma) forming a tumor (Webber et al., 2016). 
Eventually, the tumor may grow large enough to 
invade nearby organs such as the seminal vesicles or 
the rectum, kidney or the tumor cells may develop the 
ability to travel in the bloodstream and lymphatic 
system. Prostate cancer is considered 
a malignant tumor because it is a mass of cells that can 
invade other areas of the body (Chen et al., 2017). 
 
Cystatin C, a low molecular weight substance is 
removed from the bloodstream by glomerular 
filtration in the kidneys. It is expressed in all nucleated 
cells, widely distributed in human biological fluids, 
freely filtered through renal glomeruli, and uniquely 
and almost completely reabsorbed and catabolized in 
the proximal tubules (Ferguson and Waikar, 2012; 
Mori et al., 2016). Its classic role as a sensitive marker 
for renal function has been extensively studied (Yang  
et al., 2017). Urea is another renal marker but could be 
affected by a lot of factors that affects its suitability. It 
has been shown that by the action of urea transporter 
2, some urea is reabsorbed which eventually flows 
back into the thin descending limb of the tubule, 
through the collecting ducts, and into the excreted 
urine (Sands et al., 2011) thus making it one example 
of renal markers. Serum creatinine also is used in the 
detection and assessment of acute kidney injury and 
chronic kidney disease (Baumgarten, 2011). 
 
 It is a by-product of energy metabolism that is filtered 
from the blood by kidneys and is excreted into the 
urine (Tynkevich et al., 2014). The markers (urea, 
creatinine and cystatin C) were selected because they 
are readily filtered by the kidney and could easily be 
measured to assess kidney function. Therefore, there 
is need to evaluate the levels of these markers which 
will be of immense importance in the diagnosis of 
kidney dysfunction in prostate cancer. 
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MATERIALS AND METHODS 
Study Area and Subjects: The study area is Federal 
Medical Centre Ido Ekiti and its immediate 
environments, Ido-Ekiti. Ethical approval was sought 
for and obtained from Federal Medical Centre Ido-
Ekiti. The nature and purpose of research was 
explained to each participant using an informed 
consent. A total of 92 serum samples were collected 
from male subjects within 40-70 years. Patients with 
acute urinary tract infection, smokers, alcoholics, 
diabetics and kidney disorders were excluded. The 
samples consisted of 46 cases of prostate cancer 
subjects and 46 healthy subjects as control. The 
prostate cancer subjects were further grouped into 
prostate cancer subjects on therapy and not on therapy. 
There were 19 cases of prostate cancer subjects on 
therapy (Androgen receptor inhibitor and alpha 
tocopherol supplement) and 27 cases of prostate 
cancer subjects not on therapy. Venous blood (5ml) 
was collected, separated and the serum was used for 
analysis of serum urea, creatinine and cystatin C.  
 
Methods of Analysis: Determination of serum urea 
using Urease-Berthelot colorimetric method (Taylor 
and Vadgama, 1992). 
 
Principle: Urea in serum is hydrolyzed to ammonia in 
the presence of urease. The ammonia produced reacts 
with hypochlorite to form a blue coloured product 
which is directly proportional to the amount of urea 
present in the sample. 
 
Determination of serum creatinine by Jaffe’s Method 
(Spencer, 1996). 
 
Principle: Creatinine in alkaline solution reacts with 
picric acid to form a colored complex. The amount of 
the complex formed is directly proportional to the 
creatinine concentration. 
 
Determination of Cystatin C using ELISA kit 
purchased from Melsin, China (Jones et al., 2017) 
 
Principle: The ELISA strip plate provided in the kit 
has been coated with purified cystatin C antibody to 
make solid-phase antibody. Serum samples are added 
to the wells followed by cystatin C antibody labeled 
horse raddish peroxidase (HRP). After incubation and 
washing, the addition of chromogen solution changes 
the color to blue. At the effect of addition of acid, the 
colour finally becomes yellow.  
 
This color change is measured spectrophotometrically 
at wavelength of 450nm. The concentration of cystatin 
C in the samples is then determined by comparing the 
optical density of the samples to the standard curve. 
 
Statistical analysis: The data obtained were subjected 
to statistical analysis using Statistical Package for 
Social Sciences version 23. All parameters were 
expressed as mean ± standard deviation (SD) and 
results were presented on tables and chart. Student t-
test was used to determine the level of significance at 
p<0.05. 
 
RESULTS AND DISCUSSION 
In this research, cystatin C was significantly low in 
prostate cancer subjects compared with control. This 
supports the findings of Cox (2017) and Wang et al., 
(2018) where cystatin C was reported to be low in 
prostate cancer. The decreased level may be the reason 
for cancer progression since cystatin C is believed to 
play a key role in tumor suppression. Cystatin C is a 
useful marker because its concentration in body fluids 
does not depend on gender, age or muscle mass. It only 
depends on the glomerular filtration rate, which also 
makes it a good indicator of urinary tract function 
(Guo et al., 2018).  
 
On the other hand, Cystatin C was significantly high 
in prostate cancer subjects on therapy compared with 
those not on therapy which may be attributed to the 
effects of the drugs being used by the subjects. The 
result in this research shows that urea is significantly 
increased in prostate cancer subjects when compared 
with the control which agrees with the work of 
Edmund et al., (2012) where increase in urea level had 
been reported. Urea has been used as a marker of renal 
function, though it is being regarded to be inferior to 
other markers such as creatinine because blood urea 
levels are influenced by other factors such as diet and 
dehydration (Traynor et al., 2006; Ikuerowo et al., 
2013).  
 
There was no significant difference when the urea 
level in prostate cancer subjects on therapy was 
compared with those not on therapy. Also, creatinine 
was significantly increased in prostate cancer subjects 
compared with the control which agrees with the 
works of Jemal et al., (2008) which reported higher 
level in creatinine but there was no significant 
difference when those on therapy were compared with 
subjects not on therapy.   
 
Serum creatinine has been shown to be useful in the 
detection and assessment of acute kidney injury and 
chronic kidney disease (Baumgarten, 2011). 
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TABLE 1: Urea, Creatinine and Cystatin C in prostate cancer subjects and control 
 
Key: *    = significant at p < 0.05 
 
Table 2: Urea, Creatinine and Cystatin C in prostate cancer subjects on therapy and those not on therapy. 
Parameters On Therapy 
(n=19) 
Not on Therapy 
(n=27) 
T value P value 
Urea 5.93 ± 1.14 6.19 ± 0.79 -0.9080 0.369 
Creatinine 93.57 ± 16.69 90.55 ± 14.24 0.6421 0.525 
Cystatin C 75.57 ± 11.72 57.92 ± 5.57 6.0981 0.000* 
Key: *    = significant at p < 0.05 
 
 
Fig 1: Urea, Creatinine and Cystatin C relative to their age groups 
 
There was significant difference in age when the age 
groups were compared in prostate cancer subjects. It 
has been shown that the risk of development of prostate 
cancer increases significantly after the age of 50 in white 
men who have no family history of the disease and after 
the age of 40 in black men and the men who have a close 
relative with prostate cancer. This is also in agreement 
with the report which stated that prostate cancer is 
uncommon in men younger than 40 years, but 
becomes more common with advancing age (Ngugi et 
al., 2007). This study therefore showed that the levels 
of blood urea and creatinine were significantly high 
and cystatin C was significantly low in prostate cancer 
subjects compared with control. Cystatin C was 
significantly high in prostate cancer subjects on 
therapy compared with those not on therapy showing 
that the drugs had effects on the subjects. 
 
Conclusively, increased serum urea and creatinine 
concentrations as well as decreased cystatin C may 
pose higher risk of renal dysfunction in prostate cancer 
subjects. Thus, the level of serum urea, creatinine and 
cystatin C levels need to be evaluated in prostate 
cancer subjects. 
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